TY - JOUR
T1 - The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases
AU - Alijotas-Reig, Jaume
AU - Esteve-Valverde, Enrique
AU - Ferrer-Oliveras, Raquel
AU - Sáez-Comet, Luis
AU - Lefkou, Elmina
AU - Mekinian, Arsène
AU - Belizna, Cristina
AU - Ruffatti, Amelia
AU - Tincani, Angela
AU - Marozio, Luca
AU - Espinosa, Gerard
AU - Cervera, Ricard
AU - Ríos-Garcés, Roberto
AU - De Carolis, Sara
AU - Latino, Omar
AU - Llurba, Elisa
AU - Chighizola, Cecilia Beatrice
AU - Gerosa, Maria
AU - Pengo, Vittorio
AU - Lundelin, Krista
AU - Rovere-Querini, Patrizia
AU - Canti, Valentina
AU - Mayer-Pickel, Karoline
AU - Reshetnyak, Tatiana
AU - Hoxha, Ariela
AU - Tabacco, Sara
AU - Stojanovich, Ldjumila
AU - Gogou, Vassiliki
AU - Varoudis, Aikaterini
AU - Arnau, Anna
AU - Ruiz-Hidalgo, Domingo
AU - Trapé, Jaume
AU - Sos, Laia
AU - Stoppani, Carlotta
AU - Martí-Cañamares, Anna
AU - Farran-Codina, Inmaculada
PY - 2019
Y1 - 2019
N2 - Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS). Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The seven-year survey results are reported. Results: 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292 (29.2%) were in category I, 357 (35.7%) in IIa, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE) and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series, 448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no treatment showed a poor birth rate (49.6%). Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients.
AB - Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS). Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The seven-year survey results are reported. Results: 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292 (29.2%) were in category I, 357 (35.7%) in IIa, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE) and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series, 448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no treatment showed a poor birth rate (49.6%). Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients.
KW - Antiphospholipid antibody
KW - Antiphospholipid syndrome
KW - Immunology
KW - Immunology and Allergy
KW - Obstetric antiphospholipid syndrome
KW - Pregnancy autoimmune disorders
KW - Registry
KW - Antiphospholipid antibody
KW - Antiphospholipid syndrome
KW - Immunology
KW - Immunology and Allergy
KW - Obstetric antiphospholipid syndrome
KW - Pregnancy autoimmune disorders
KW - Registry
UR - http://hdl.handle.net/10807/132939
UR - http://www.elsevier.com/locate/autrev
U2 - 10.1016/j.autrev.2018.12.006
DO - 10.1016/j.autrev.2018.12.006
M3 - Article
SN - 1568-9972
VL - 18
SP - 406
EP - 414
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
ER -